Document is current

Article History

Received: 23 June 2022

Accepted: 16 September 2022

First Online: 21 October 2022

Declarations

:

: Not applicable.

: Not applicable.

: Taku Maruki has received lecture fees from Meiji Seika Pharma. Tomohiro Utsumi has received lecture fees from Eisai. Masahiro Takeshima has received lecture fees from Daiichi Sankyo Company, Sumitomo Dainippon Pharma, Meiji Seika Pharma, Viatris Pharmaceuticals Japan, Yoshitomi Pharmaceutical, and Daiichi Sankyo Company, as well as research grants from Otsuka Pharmaceutical, Eisai, and Shionogi outside the submitted work. Yu Fujiwara declares that there is no conflict of interest. Marie Matsui declares that there is no conflict of interest. Yumi Aoki declares that there is no conflict of interest. Hiroyuki Toda has received lecture fees from Sumitomo Dainippon Pharma, Otsuka Pharmaceutical, Takeda Pharmaceutical, and Pfizer. Norio Watanabe declares that there is no conflict of interest. Koichiro Watanabe has received manuscript fees or lecture fees from Eisai, Eli Lilly, Janssen Pharmaceutical, Kyowa Pharmaceutical, Lundbeck, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, MSD, Otsuka Pharmaceutical, Pfizer, Shionogi, Sumitomo Dainippon Pharma, Takeda Pharmaceutical, Viatris, and Yoshitomi as well as research/grant support from Daiichi Sankyo, Eisai, Mitsubishi Tanabe Pharma, Meiji Seika Pharma, MSD, Otsuka Pharmaceutical, Pfizer, and Sumitomo Dainippon Pharma. He is also a consultant for Boelinger Inglheim, Eisai, Eli Lilly, Kyowa Pharmaceutical, Lundbeck, Luye Life Sciences Group, Mitsubishi Tanabe Pharma, Otsuka Pharmaceutical, Sumitomo Dainippon Pharma, Taisho Toyama Pharmaceutical, Takeda Pharmaceutical, and Viatris., Yoshikazu Takaesu has received lecture fees from Takeda Pharmaceutical, Sumitomo Dainippon Pharma, Otsuka Pharmaceutical, Meiji Seika Pharma, Kyowa Pharmaceutical, Eisai, MSD, and Yoshitomi, as well as research funding from Otsuka Pharmaceutical, Meiji Seika Pharma, MSD, and Eisai.